A new frontier in biopharmaceutical science is being defined by the sophisticated engineering of bispecific antibodies. These are not naturally occurring proteins; they are custom-designed molecules endowed with a bifunctional capability, allowing them to engage two distinct targets simultaneously. The most celebrated modality within this class, the Bispecific T-cell Engager (BiTE), acts as a...